Rosemary: Traditional Use, Constituents and Evidence

My nan kept a rosemary bush by the back gate at her place in Stirling , the same one she'd snip for lamb roasts and, without much ceremony, steep for a hair rinse. She never called it medicine. She just knew it worked for her, in the way that knowledge gets passed hand to hand over generations before anyone thinks to write it down. I've spent a fair bit of time since then trying to work out what the science actually makes of that confidence.

The answer is: complicated. Rosemary (Salvia rosmarinus, formerly Rosmarinus officinalis) is one of those plants that carries an enormous weight of traditional use, a genuinely interesting phytochemical profile, and a research base that is real but frequently overstated. Worth unpacking properly.

A brief history of a very old herb

Rosemary has been cultivated around the Mediterranean since at least antiquity. Greek and Roman writers referenced it; medieval European herbalists placed it high in their pharmacopoeias; it featured in the 1652 edition of Nicholas Culpeper's Complete Herbal as a herb "of the Sun" suited to warming and strengthening. Across North Africa, the Middle East, and later the Americas through colonial exchange, it found its way into domestic medicine almost everywhere it could be grown.

Traditional uses varied considerably by region but tended to cluster around a few themes: topical preparations for the scalp and skin, aromatic use, culinary preservation (important in its own right , rosemary's antioxidant properties were practically useful long before anyone named them), and preparations taken internally as a bitter tonic. As a phytomedicine, it sits in a large category of culinary herbs whose traditional medicinal reputations preceded any formal investigation by centuries.

The 2013 reclassification of Rosmarinus officinalis into the broader Salvia genus , based on phylogenetic analysis; didn't change the plant, but it's a useful reminder that taxonomy and folk knowledge travel at different speeds.

Key constituents: what's actually in it

Rosemary's phytochemistry is layered. The essential oil fraction, dominated by 1,8-cineole (also called eucalyptol), camphor, and alpha-pinene, gives the plant its characteristic scent and accounts for much of the interest in aromatherapy contexts. The proportions of these volatiles shift depending on growing region, harvest time, and the specific chemotype; Spanish rosemary and Tunisian rosemary, for instance, can have quite different 1,8-cineole to camphor ratios.

Beyond the volatile fraction, the phenolic compounds get most of the research attention. Rosmarinic acid is the one you'll see cited most often: a hydroxycinnamic acid ester with documented antioxidant activity in laboratory settings. Carnosic acid and carnosol are diterpene phenols found in higher concentrations in the leaf; they're the main compounds behind rosemary extract's use as a natural preservative in the food industry, a genuinely large commercial application that tends to get overlooked in the wellness conversation.

The terpene profile also includes beta-pinene, linalool, and smaller amounts of beta-caryophyllene. Beta-caryophyllene is particularly interesting from a broader phytochemistry perspective; it's a bicyclic sesquiterpene that has attracted research attention for its interactions with the endocannabinoid system, specifically as a ligand for the CB2 receptor. Rosemary doesn't contain it in high concentrations, but it's a good illustration of how terpene research across different plants keeps looping back to shared molecular targets.

There are also flavonoids (luteolin, apigenin, diosmin), ursolic acid, and various caffeic acid derivatives. This is a plant with real chemical complexity, which is partly why isolating any single mechanism from whole-herb preparations is genuinely hard.

What the research looks like, and where it stops short

Honestly, the literature on rosemary is a good case study in how to read phytomedicine research carefully. There's a lot of it. Much of it is in vitro (cell culture studies) or uses animal models. Clinical trials in humans are far fewer, tend to have small sample sizes, short durations, and; a recurring issue, variable extract compositions that make cross-study comparison difficult.

Rosmarinic acid has been the subject of considerable in vitro work examining its behaviour in oxidative stress models. Carnosic acid and carnosol have been studied in laboratory contexts. The essential oil components, especially 1,8-cineole, have a decent body of work around their chemistry and how they interact with biological membranes. But the hard yards from lab model to human clinical evidence are largely unfinished. That's not a criticism unique to rosemary, it describes the state of phytomedicine research broadly; but readers deserve to know it.

The aromatherapy research, which looks at inhalation of rosemary essential oil and self-reported outcomes like alertness or mood, is a particular area where I'd argue the popular press routinely runs ahead of what the data can actually support. The studies exist. They're small, the methodology varies, and effect sizes are generally modest. None of this constitutes evidence that rosemary aromatherapy treats or prevents any condition.

If you want a useful framework for thinking about standardised extracts versus whole-herb preparations, and why that distinction matters for research interpretation, it's worth spending time with that concept before drawing conclusions from any single rosemary study.

Regulation in Australia: what to know

In Australia, rosemary and rosemary-derived ingredients appear across several regulatory categories depending on how a product is presented and what claims are made for it.

Culinary rosemary is, obviously, a food. Rosemary extract (standardised for rosmarinic acid or total phenolics) appears as an ingredient in Listed complementary medicines on the Australian Register of Therapeutic Goods (ARTG). A Listed medicine, carrying an "AUST L" number, is self-assessed by the sponsor for safety and quality, and the TGA does not evaluate the evidence for efficacy before listing. This is a meaningful distinction: AUST L listing does not mean the TGA has assessed or endorsed the claimed benefits of the product.

Under the TGA's current framework, complementary medicine sponsors must hold evidence for any health claims they make, but that evidence standard is lower than the Registered (AUST R) pathway used for assessed medicines. Consumers who see rosemary extract products on shelves with health claims attached should understand that those claims have not been independently verified by the regulator before the product reaches them.

There are no import restrictions on rosemary comparable to, say, the kava import controls that apply under Australian biosecurity and customs rules for certain Pacific Island kava preparations. Rosemary moves freely as a food and as a cosmetic ingredient. High-concentration essential oil products warrant their own care; camphor-containing preparations have specific limits under the Poisons Standard for certain applications, particularly products intended for use near infants, but rosemary leaf and standard rosemary extracts sit in ordinary commercial channels.

Good manufacturing practice (GMP) requirements do apply to therapeutic goods sponsors, so the manufacturing quality of an ARTG-listed product should meet a defined standard, even if the efficacy claims haven't been independently assessed.

The bioavailability question

One piece of the puzzle that rarely makes it into popular rosemary articles: oral bioavailability of rosmarinic acid and the diterpene phenols is genuinely variable. These compounds are subject to gut metabolism; first-pass metabolism shapes what actually reaches systemic circulation and in what form. The fact that a compound shows activity in a cell culture at a given concentration doesn't mean that concentration is achievable in human tissue from a dietary or supplement dose. This gap between in vitro potency and in vivo relevance is one of the most commonly glossed-over issues in phytomedicine communication, and rosemary research is no exception.

Where it sits in the broader picture

Rosemary is a plant with genuine phytochemical interest, a long and geographically widespread traditional history, and a research base that supports continued scientific curiosity without yet supporting strong therapeutic conclusions. That's not a dismissal. The chemistry is real; some of the mechanisms under investigation are plausible; the ethnobotanical record is worth taking seriously as a starting point for inquiry.

But the popular wellness framing, which can run from mildly overstated to genuinely misleading; does the plant a disservice in the long run. Rosemary doesn't need inflated claims. It has been part of human food and culture for millennia, its antioxidant properties have real commercial utility, and the terpene chemistry connects in interesting ways to broader conversations about how plants produce and deploy volatile compounds. That's quite enough to be going on with.

My nan's rosemary bush is still there, for what it's worth. The current owners have let it get enormous. I think she'd approve.

Sources

• Listed Medicines, Evidence Guidelines, Therapeutic Goods Administration (TGA)
• Phytochemistry and biological activities of Rosmarinus officinalis; NCBI / PubMed
• Rosmarinic acid: a review of its chemistry, pharmacology and biological activities, NCBI / PubMed
• Good Manufacturing Practice (GMP), Therapeutic Goods Administration (TGA)

, Naomi Ellison, Botanical & phytomedicine writer